Alkermes plc (ALKS) Receives Analyst Rating

Alkermes plc (ALKS) : Zacks Investment Research ranks Alkermes plc (ALKS) as 2, which is a Buy recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. The average broker rating of 4 research analysts is 1.83, which indicates as a Buy.

Alkermes plc (ALKS) : Currently there are 3 street experts covering Alkermes plc (ALKS) stock. The most bullish and bearish price target for the stock is $66 and $60 respectively for the short term. The average price target of all the analysts comes to $62.67. The estimated standard deviation from the target is $3.06.


Also, In a research note released to the investors, Barclays maintains its rating on Alkermes plc (NASDAQ:ALKS).The analysts at the brokerage house have a current rating of Overweight on the shares. In a recent information released to the investors, Barclays raises the new price target from $65 per share to $66 per share. The rating by the firm was issued on July 29, 2016.

Alkermes plc (NASDAQ:ALKS): After opening at $47.67, the stock dipped to an intraday low of $46.86 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $48.45 and the buying power remained strong till the end. The stock closed at $48.34 for the day, a gain of 1.45% for the day session. The total traded volume was 593,712. The stocks close on the previous trading day was $47.65.

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.